Editorial Perspectives On Cell Line Development

  1. IPSCs For Democratized Cell Therapy 6/7/2022

    Dr. Daniel Teper and his team at Cytovia Therapeutics have developed a unique combination of candidates designed to improve access to safe and affordable "off-the-shelf" cell therapies. Founded just four years ago, the company is preparing multiple clinical trials of IPSC-derived therapies, which Dr. Teper says lend to a consistent, scalable manufacturing process. 

  2. Will Anellovirus Vectors Solve Immunogenicity Challenges? 5/20/2022

    Ring Therapeutics is building a first-of-its-kind viral vector platform based on a commensal virus that flies under the immune system’s radar. If its odds-beating CEO is any indication of its success, the company just might beat the immunogenicity challenge.

  3. How To Build A Genomic Medicine Biotech 5/11/2022

    SparingVision CEO Stephane Boissel took the reins of a fledgling, single-asset gene therapy company born of academic research and quickly built a well-funded startup with a deepening pipeline of ocular disease candidates. He told the Business of Biotech how it happened.

  4. The CAR T Speed Show 5/9/2022

    Some mainstream, high-profile research out of the University of Pennsylvania has re-energized emerging cell therapy developers’ focus on manufacturing and administration speed. Speedy cell therapy pioneer EXUMA Biotech provides an update on its approach.

  5. Who Said mAbs Were Easy? 4/27/2022

    Under the leadership of CEO Mondher Mahjoubi, M.D., oncology-focused biotech Innate Pharma is developing therapeutic antibodies that harness the immune system to fight cancer. The company is making strides with some next-gen, complex tri- and tetra-specific antibodies—and Dr. Mahjoubi isn't afraid to face the CMC challenges that come with the job. 

  6. Ocular + Auditory Cell Therapies: Lineage Cell Therapeutics 2.0 4/25/2022

    On the heels of a lucrative deal with Roche/Genentech for its Phase I/IIa dry age-related macular degeneration candidate, Lineage Cell Therapeutics is fording new waters with a promising auditory neuropathy spectrum disorder candidate. CEO Brian Culley shares the strategy.

  7. Inside The Allogeneic NK Cell Therapy Effort 3/21/2022

    With its genetically engineered induced pluripotent stem cell-derived allogeneic natural killer cell technology, Shoreline Biosciences aims to overcome what Chairman and CEO Kleanthis Xanthopoulos calls the tallest barrier in the space: patient accessibility.

  8. Regenerating The Vasculature With Bioengineered Human Tissue 2/23/2022

    With two phase 3 trials resuting in its bioengineered blood vessels being implanted in some 460 human patients, regenerative medicine pioneer Humacyte is finding its footing in the $150 billion vascular repair, reconstruction, and replacement market. Now it's preparing to reinvent treatment for Type 1 Diabetes.

  9. A Drug Discovery Alliance For The Ages 2/14/2022

    With the renewal of their Collaborative Research Agreement, the La Jolla Institute for Immunology and Kyowa Kirin North America extended a more than 30-year partnership that continues to bear fruit. As many good and longstanding friendships do, it all started with beer. Here’s why the collaboration stands the test of time.

  10. Vaccine Manufacturing: Chasing COVID's Long Tail 1/31/2022

    A host of biopharma companies continue to pour resources into coronavirus vaccine candidates. Among them, iBio stands out with a unique target region (hint: it’s not a spike protein) and an even more unique manufacturing paradigm (hint: it’s not mRNA).